Ryan Deschner's Stock Ratings

Raymond James Analyst

Ryan Deschner is an analyst at Raymond James. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/24/2024

Overall Average Return

-10.3%

Smart Score

12.4%

Overall Average Return Percentile

19th

Number of Ratings

2
Buy NowGet Alert
07/25/2024SPRYBuy Now
ARS Pharmaceuticals
$11.1960.86% → $18Initiates → OutperformGet Alert
06/18/2024OMGABuy Now
Omega Therapeutics
$1.81562.98% → $12Initiates → OutperformGet Alert

Recent Analyst Stock Rating News

Expert Ratings For Omega Therapeutics
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.
What's Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).
Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free